Details for Patent: 6,875,445
✉ Email this page to a colleague
Summary for Patent: 6,875,445
Title: | Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption |
Abstract: | A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract. |
Inventor(s): | Dennett, Jr.; Edmund V. (Milton, MA), Raleigh, Jr.; Robert M. (Pembroke, MA), Aronson; Bruce H. (Sharon, MA) |
Assignee: | Nabi Biopharmaceuticals (Boca Raton, FL) |
Application Number: | 10/279,598 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,875,445 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; Delivery; Device; Use; |
Drugs Protected by US Patent 6,875,445
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |